2. Epigenetics TGF-beta/Smad
  3. PKC
  4. Go 6983

Go 6983  (Synonyms: Gö 6983; Goe 6983)

Cat. No.: HY-13689 Purity: 99.32%
SDS COA Handling Instructions

Molarity Calculator

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

For research use only. We do not sell to patients.

Go 6983 Chemical Structure

Go 6983 Chemical Structure

CAS No. : 133053-19-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 117 In-stock
Solution
10 mM * 1 mL in DMSO USD 117 In-stock
Solid
5 mg USD 106 In-stock
10 mg USD 172 In-stock
50 mg USD 541 In-stock
100 mg USD 911 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 63 publication(s) in Google Scholar

Go 6983 Related Antibodies

Top Publications Citing Use of Products

57 Publications Citing Use of MCE Go 6983

WB
RT-PCR
IF

    Go 6983 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 7;9(2):165.  [Abstract]

    Western blot analysis of MCF-7 cells treated with Tan IIA at the specified concentrations for the expression of cytosolic PKC isoforms. The compound Go 6983 (GO, 20 μM) is included as a positive control.

    Go 6983 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Sep 3;503(1):62-70.  [Abstract]

    BMMs are incubated in serum-free medium and pretreated with or without Go6983 (0, 2.5 μM) for 4 h. Next, the BMMs are stimulated by RANKL (50 ng/mL) for the indicated times (0, 15, 30, 60 min). Additionally, the BMM lysates are analyzed by western blotting.

    Go 6983 purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2016 Aug 30;192:26-33.  [Abstract]

    Effect of PKC inhibitor on NF-kB DNA binding activity and NFAT inhibitor on NFATc1 DNA binding activity. Lane N is negative control; lane 1 is control group; lane 2 is S. uberis group; lane 3 is pre-treated with 2 μM Go 6983; lane 4 is pre-treated with 5 μM Go 6983; lane 5 is pre-treated with 10 μM Go 6983.

    Go 6983 purchased from MedChemExpress. Usage Cited in: J Appl Toxicol. 2016 Nov;36(11):1409-17.   [Abstract]

    Quantitative analysis of the intensity of GLT-1 expression relative to GAPDH in the indicated groups. Cells are pre-treated with Ca2+-signaling blocker BAY-a-1040 (25 nM) for 30min before TCDD stimulation. The PKC inhibitor staurosporine (10 nM) and Go 6983 (1 μM) is applied 2 h before adding TCDD.

    Go 6983 purchased from MedChemExpress. Usage Cited in: J Appl Toxicol. 2016 Nov;36(11):1409-17.   [Abstract]

    Immunofluorescence staining of PKC after pre-treatment with the Ca2+-signaling blocker and the PKC inhibitor. PKC is enriched in cytoplasmor perinucleus in untreated C6 cells (a-c), Go 6983-treated cells (g-i) or BAY-a-1040-treated cells (m-o). TCDD induces PKC translocation to the membrane in C6 glioma cells (d-f ).

    Go 6983 purchased from MedChemExpress. Usage Cited in: J Appl Toxicol. 2016 Nov;36(11):1409-17.   [Abstract]

    Protein levels of GLT-1 analyzed by Western blotting in C6 cells then treated with TCDD for 12 h. Cells are pre-treated with Ca2+-signaling blocker BAY-a-1040 (25 nM) for 30min before TCDD stimulation. The PKC inhibitor staurosporine (10 nM) and Go 6983 (1 μM) is applied 2 h before adding TCDD.

    View All PKC Isoform Specific Products:

    View All Isoforms
    PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

    IC50 & Target[1]

    PKCγ

    6 nM (IC50)

    PKCα

    7 nM (IC50)

    PKCβ

    7 nM (IC50)

    PKCδ

    10 nM (IC50)

    PKCζ

    60 nM (IC50)

    PKCμ

    20000 nM (IC50)

    In Vitro

    Go 6983 inhibits PKCμ with IC50 of 20 μM, and the pther PKC isoenzymes can be suppressed by Go 6983 with IC50 values from 7 to 60 nM[1]. Go 6983 (100 nM) significantly reduces PMN adherence to the endothelium and infiltration into the myocardium compared with I/R + PMN hearts, and significantly inhibits superoxide release from PMNs by 90 +/- 2% in rat hearts[2]. Go 6983 (200 nM) has a reduced cardioprotective effect compared with the cardioprotective Go 6983 concentrations (50 and 100 nM) despite inhibiting PMN superoxide release by 99%[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Go 6983 Related Antibodies
    Molecular Weight

    442.51

    Formula

    C26H26N4O3
    CAS No.
    Appearance

    Solid

    Color

    Pink to red

    SMILES

    O=C(C(C1=CN(CCCN(C)C)C2=C1C=C(OC)C=C2)=C3C4=CNC5=C4C=CC=C5)NC3=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (225.98 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.2598 mL 11.2992 mL 22.5984 mL
    5 mM 0.4520 mL 2.2598 mL 4.5197 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.65 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (5.65 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.32%

    SDS (393 KB)

    COA (256 KB) HNMR (260 KB) RP-HPLC (244 KB) LCMS (96 KB)

    Handling Instructions (2659 KB)
    References
    Kinase Assay
    [1]

    Phosphorylation reactions are carried out in a total volume of 100 μL, containing buffer C (50 mM Tris-HCl, pH 7.5, 10 mM β-mercaptoethanol), 4 mM MgCl2, 10 μg PS, 100 nM TPA, 5 μL of a Sf158 cell extract as a source of recombinant PKCμ or of Sf9 cell extracts as a source of other recombinant PKC isoenzymes, 10 μg of syntide 2 as substrate, and 35 μM ATP containing 1 μCi [γ-32P]ATP. In some experiments, PS and TPA are omitted or various inhibitors at concentrations indicated in the text are added. After incubation for 10 min at 30°C, the reaction is terminated by transferring 50 μL of the assay mixture onto a 20 mm square piece of phosphocellulose paper, which is washed 3 times in deionized water and twice in acetone. The radioactivity on each paper is determined by liquid scintillation counting.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2598 mL 11.2992 mL 22.5984 mL 56.4959 mL
    5 mM 0.4520 mL 2.2598 mL 4.5197 mL 11.2992 mL
    10 mM 0.2260 mL 1.1299 mL 2.2598 mL 5.6496 mL
    15 mM 0.1507 mL 0.7533 mL 1.5066 mL 3.7664 mL
    20 mM 0.1130 mL 0.5650 mL 1.1299 mL 2.8248 mL
    25 mM 0.0904 mL 0.4520 mL 0.9039 mL 2.2598 mL
    30 mM 0.0753 mL 0.3766 mL 0.7533 mL 1.8832 mL
    40 mM 0.0565 mL 0.2825 mL 0.5650 mL 1.4124 mL
    50 mM 0.0452 mL 0.2260 mL 0.4520 mL 1.1299 mL
    60 mM 0.0377 mL 0.1883 mL 0.3766 mL 0.9416 mL
    80 mM 0.0282 mL 0.1412 mL 0.2825 mL 0.7062 mL
    100 mM 0.0226 mL 0.1130 mL 0.2260 mL 0.5650 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Go 6983 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Go 6983133053-19-7Gö 6983 Goe 6983Go6983Go-6983Goe6983Goe 6983Goe-6983PKCProtein kinase CInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Go 6983
    Cat. No.:
    HY-13689
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.